RLAY Relay Therapeutics, Inc. Insider Trading

CFO Catinazzo sells 187,163 shares ($3.2M) via scheduled 10b5-1 plan; retains 177,461 shares plus 223,440 stock options.

Thomas Catinazzo, CFO of Relay Therapeutics, executed 4 separate sales totaling 187,163 shares for $3,176,864.79 on 2026-06-22 at a blended average price of $16.97, reducing his direct holdings by 51.3% to 177,461 shares. The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted 2025-10-30, making it scheduled rather than discretionary. After the sale, Catinazzo retains 223,440 shares through stock option holdings, meaning his economic interest in the company remains substantial. The sale occurs against a backdrop of strong recent stock performance (30-day change +33.3%, 90-day change +78.2%) and an unprofitable company (most recent quarter revenue $3.0M, full-year net income $-73.3M), though the stock is currently at $18.03, above the transaction prices.

Relay Therapeutics President of R&D sold 93,456 shares at $16.94 via pre-arranged 10b5-1 plan; 418,557 shares remain

Donald A Bergstrom, President of R&D, executed a scheduled sale of 93,456 shares at $16.94 on 2026-06-22 under a 10b5-1 trading plan adopted on 2025-10-30, reducing his holdings by 18.3% to 418,557 shares. The sale occurred during a period of significant stock appreciation—the 90-day change shows +78.2% and 30-day change shows +33.3%—though the current price of $18.03 reflects a -4.2% pullback from the 52-week high of $18.83. This transaction is structured and non-discretionary, reflecting a pre-planned divestment rather than a reactive market response. The company remains unprofitable (net income $-73.3M) despite strong revenue growth of +53.4%, creating a backdrop where insider reduction of holdings occurs amid operational losses and elevated stock valuation relative to near-term fundamentals.

CEO Patel sells 215,506 shares (19.6% of holdings) across 2 transactions for $818,399.50 at $3.80–$3.85; stock down 63.5% from 52-week high.

Patel Sanjiv, President and CEO of Relay Therapeutics, executed 2 separate sales totaling 215,506 shares (215.5K shares) for $818,399.50 on February 11 and February 13, 2025, reducing his stake by 19.6% from 1,098,595 shares to 883,089 shares. The sales occurred at $3.85 and $3.70 per share (blended average $3.80), compared to the current price of $3.96—within the stock's recent range but -63.5% below its 52-week high of $10.84. Across his cross-ticker open-market history, Patel has executed 5 prior sells with an average 90-day well-timed rate of 100.00% and an average 90-day return of -31.5%, indicating a pattern of selling before subsequent declines. At RLAY specifically, his 2 measurable prior sales (July 2024) both posted negative 90-day returns (-31.8% and -31.2%), consistent with this pattern. Against this backdrop, a CEO liquidating roughly one-fifth of his holdings in a company that reported unprofitable operations (net income of $-88,105,000.00 for the latest full fiscal year) and whose stock has declined 22.4% in the past 90 days and 8.9% in the past 30 days warrants investor attention, particularly given the company's reliance on its $10,007,000.00 quarterly revenue and the demonstrated historical tendency of this insider's sales to precede further price weakness.

CEO Sanjiv Patel sold 375,000 shares (65.3% of holdings) for $1.8M over 3 days, reversing prior well-timed exit pattern at unprofitable biotech.

Sanjiv Patel, President and CEO of Relay Therapeutics, sold 375,000 shares (375.0K shares) totaling $1,762,500.00 across 3 separate sales from January 21–23, 2025, at prices ranging from $4.52 to $4.80, reducing his holdings by 65.3% from 574,548 shares to 199,548 shares. This represents a substantial reduction in CEO position ownership of an unprofitable biotech company (net income $-88,105,000.00 for the full year) generating only $10,007,000.00 in quarterly revenue. Notably, Patel's two prior open-market sales at RLAY (July 2024) each showed strong timing, with both resulting in 90-day returns of -20.6% and -21.4% respectively—indicating a consistent pattern of selling before subsequent declines—with his cross-ticker track record showing a 100.00% well-timed rate across 2 prior sells and 90-day performance averaging -31.5%. However, the 30-day change since this January filing stands at +15.6%, contrasting with his historical post-sale decline patterns; the 52-week trading range of $3.81–$10.84 places current price $4.89 at 54.9% below the high, marking the stock in a significantly depressed state relative to its recent range. The substantial scale of this position reduction by the CEO during a period of unprofitability and weak revenue, combined with his demonstrated timing acuity in prior exits, warrants investor scrutiny of ongoing business fundamentals and management confidence signals.

RLAY CEO Patel sells 86,706 shares across 2 transactions for $790.9K at $9.12 avg; stock now $8.22

Sanjiv Patel, President and CEO, executed 2 separate sales totaling 86,706 shares for $790,923.42 at a blended average price of $9.12 on July 25-26, 2024. The sales reduced his holdings from 852,836 shares to 766,130 shares, a -10.2% reduction. RLAY is an unprofitable biotech company with $10.0M quarterly revenue and a net loss of $81.4M in its most recent full year, though annual revenue grew 1749.8%. The stock currently trades at $8.22, 34.8% below its 52-week high of $12.60 but up 26.1% over both the prior 30 and 90 days. The CEO sold at prices $9.07–$9.16, above the current $8.22 level, which occurred after a recent recovery phase in the stock.